{
    "ticker": "MLTX",
    "name": "Molecular Templates, Inc.",
    "description": "Molecular Templates, Inc. is a biotechnology company focused on the development of novel therapeutics for the treatment of various cancers. Founded in 2013, the company utilizes its proprietary platform technology, known as the Engineered Toxin Bodies (ETB), to create differentiated therapeutics that deliver targeted cell-killing agents to cancer cells. This innovative approach aims to enhance the efficacy and safety of cancer treatments while minimizing side effects associated with traditional therapies. Molecular Templates is advancing several product candidates through clinical trials, including its lead candidate, MT-3724, which targets CD20-positive cancers. The company is also exploring a pipeline of additional ETB-based candidates designed to treat a range of malignancies. With a commitment to improving patient outcomes, Molecular Templates is dedicated to addressing unmet medical needs in oncology through its cutting-edge research and development efforts.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Austin, Texas, USA",
    "founded": "2013",
    "website": "https://www.moleculartemplates.com",
    "ceo": "Eric Poma",
    "social_media": {
        "twitter": "https://twitter.com/moleculartmplts",
        "linkedin": "https://www.linkedin.com/company/molecular-templates-inc/"
    },
    "investor_relations": "https://investors.moleculartemplates.com",
    "key_executives": [
        {
            "name": "Eric Poma",
            "position": "CEO"
        },
        {
            "name": "Michael W. McCarthy",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology Therapeutics",
            "products": [
                "MT-3724",
                "MT-4016"
            ]
        }
    ],
    "seo": {
        "meta_title": "Molecular Templates, Inc. | Innovative Cancer Therapeutics",
        "meta_description": "Explore Molecular Templates, Inc., a biotechnology company developing novel cancer treatments using its Engineered Toxin Bodies platform. Learn about our pipeline and commitment to oncology.",
        "keywords": [
            "Molecular Templates",
            "Biotechnology",
            "Cancer Treatment",
            "Oncology",
            "ETB",
            "MT-3724"
        ]
    },
    "faq": [
        {
            "question": "What is Molecular Templates known for?",
            "answer": "Molecular Templates is known for developing innovative oncology therapeutics using its proprietary Engineered Toxin Bodies technology."
        },
        {
            "question": "Who is the CEO of Molecular Templates?",
            "answer": "Eric Poma is the CEO of Molecular Templates, Inc."
        },
        {
            "question": "Where is Molecular Templates headquartered?",
            "answer": "Molecular Templates is headquartered in Austin, Texas, USA."
        },
        {
            "question": "What are Molecular Templates' main products?",
            "answer": "Molecular Templates' main products include MT-3724 and MT-4016, which are in development for various cancers."
        },
        {
            "question": "When was Molecular Templates founded?",
            "answer": "Molecular Templates was founded in 2013."
        }
    ],
    "competitors": [
        "CLVS",
        "KITE",
        "ADAP",
        "ZIOP"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BMY",
        "JNJ"
    ]
}